U. La Rocca, G. Giovannetti, F. Maldarelli, Mirella Farinelli, M. Piazzolla, A. Angeloni, F. Pugliese, S. Coluzzi
Dear Editor, In 2019 a severe acute respiratory syndrome (SARS-CoV-2), caused by a novel coronavirus (2019-nCoV), was described in Wuhan City, Hubei Province, China, which then rapidly spread and evolved into a pandemic. As of 5 July 2021, 183,298,109 confirmed cases of coronavirus disease (COVID-19) and 3,971,687 deaths all over the world have been reported. Italy is one of the most involved countries, reaching 4,259,909 confirmed cases (as of 2 July 2021) and 127,566 deaths. Clinical presentations of SARS-CoV-2 are various. Most infected patients are asymptomatic, others develop mild symptoms like dry cough, sore throat, and fever, with a spontaneous resolution. Some cases evolve into pulmonary oedema, severe pneumonia, acute respiratory distress syndrome (ARDS), and septic shock resulting in organ failure. Most-used treatments are chloroquine and hydroxychloroquine, claimed to block viral entry into cells and have immunomodulatory effects, lopinavir/ritonavir and other antivirals, corticosteroids, anti-cytokines or immunomodulatory agents (tocilizumab, a monoclonal antibody IL-6 receptor antagonist), low-molecular-weight heparin (LMWH) to limit the risk of an associated coagulopathy and disseminated intravascular coagulation (DIC). The WHO has published guidelines to manage the blood supply in response to the COVID-19 pandemic. The guidance underlines the role of blood services in assessing, planning, and responding to the outbreak. In fact, lockdown and social distancing may lead to limited blood resources. Moreover, while blood transfusion requirement may decrease as the health care system is focused on treating COVID-19 patients, thus deferring other clinical interventions, transfusions will still be necessary for emergency situations and to support COVID-19 patients with severe sepsis. Critical patients may develop anaemia as a consequence of multifactorial and complex pathogenesis. Phlebotomies and other surgical procedures, coagulopathies, pathogen-associated haemolysis, hypoadrenalism, and nutritional deficiencies, as well as the concomitant administration of different drugs, may cause Haemoglobin (Hb) to drop. Decreased erythropoietin production and/or activity could be the consequence of inflammatory cytokines such as IL-1 and TNF-α. The risk in COVID-19 patients is even higher due to the well-known pro-haemolytic effect of hydroxychloroquine, especially in G6PDHdeficient individuals, even if there are few findings supporting the necessity for G6PDH deficiency screening before starting this drug. Here we report the results of a retrospective evaluation of blood transfusion supply in patients (pts) affected by COVID-19, admitted to Policlinico Umberto I, Sapienza University of Rome, during the epidemic outbreak, taking into account treatments, comorbidities, clinical and laboratory parameters, especially those related to RBC transfusion. From the 1 March 2020 to 27 April 2020, 71 patients with COVID-19 infection were admitted to Policl
{"title":"Blood transfusion needs in COVID‐19 patients: An observational prospective unicentric study","authors":"U. La Rocca, G. Giovannetti, F. Maldarelli, Mirella Farinelli, M. Piazzolla, A. Angeloni, F. Pugliese, S. Coluzzi","doi":"10.1111/tme.12886","DOIUrl":"https://doi.org/10.1111/tme.12886","url":null,"abstract":"Dear Editor, In 2019 a severe acute respiratory syndrome (SARS-CoV-2), caused by a novel coronavirus (2019-nCoV), was described in Wuhan City, Hubei Province, China, which then rapidly spread and evolved into a pandemic. As of 5 July 2021, 183,298,109 confirmed cases of coronavirus disease (COVID-19) and 3,971,687 deaths all over the world have been reported. Italy is one of the most involved countries, reaching 4,259,909 confirmed cases (as of 2 July 2021) and 127,566 deaths. Clinical presentations of SARS-CoV-2 are various. Most infected patients are asymptomatic, others develop mild symptoms like dry cough, sore throat, and fever, with a spontaneous resolution. Some cases evolve into pulmonary oedema, severe pneumonia, acute respiratory distress syndrome (ARDS), and septic shock resulting in organ failure. Most-used treatments are chloroquine and hydroxychloroquine, claimed to block viral entry into cells and have immunomodulatory effects, lopinavir/ritonavir and other antivirals, corticosteroids, anti-cytokines or immunomodulatory agents (tocilizumab, a monoclonal antibody IL-6 receptor antagonist), low-molecular-weight heparin (LMWH) to limit the risk of an associated coagulopathy and disseminated intravascular coagulation (DIC). The WHO has published guidelines to manage the blood supply in response to the COVID-19 pandemic. The guidance underlines the role of blood services in assessing, planning, and responding to the outbreak. In fact, lockdown and social distancing may lead to limited blood resources. Moreover, while blood transfusion requirement may decrease as the health care system is focused on treating COVID-19 patients, thus deferring other clinical interventions, transfusions will still be necessary for emergency situations and to support COVID-19 patients with severe sepsis. Critical patients may develop anaemia as a consequence of multifactorial and complex pathogenesis. Phlebotomies and other surgical procedures, coagulopathies, pathogen-associated haemolysis, hypoadrenalism, and nutritional deficiencies, as well as the concomitant administration of different drugs, may cause Haemoglobin (Hb) to drop. Decreased erythropoietin production and/or activity could be the consequence of inflammatory cytokines such as IL-1 and TNF-α. The risk in COVID-19 patients is even higher due to the well-known pro-haemolytic effect of hydroxychloroquine, especially in G6PDHdeficient individuals, even if there are few findings supporting the necessity for G6PDH deficiency screening before starting this drug. Here we report the results of a retrospective evaluation of blood transfusion supply in patients (pts) affected by COVID-19, admitted to Policlinico Umberto I, Sapienza University of Rome, during the epidemic outbreak, taking into account treatments, comorbidities, clinical and laboratory parameters, especially those related to RBC transfusion. From the 1 March 2020 to 27 April 2020, 71 patients with COVID-19 infection were admitted to Policl","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"193 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134541737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Holloway, Chantal Campbell, Ridwaanah Ali, Larkin Davenport Huyer, D. Hart, J. Haw, S. Brennenstuhl, Q. Grundy
To understand motivations and deterrents to donate COVID‐19 convalescent plasma for a clinical trial and determine whether they predict intention to donate source plasma.
{"title":"A critical contribution in a time of crisis: Examining motivations and deterrents to COVID‐19 convalescent plasma donation and future donation intentions among prospective Canadian donors","authors":"K. Holloway, Chantal Campbell, Ridwaanah Ali, Larkin Davenport Huyer, D. Hart, J. Haw, S. Brennenstuhl, Q. Grundy","doi":"10.1111/tme.12875","DOIUrl":"https://doi.org/10.1111/tme.12875","url":null,"abstract":"To understand motivations and deterrents to donate COVID‐19 convalescent plasma for a clinical trial and determine whether they predict intention to donate source plasma.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"86 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126044329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Dhiman, V. Gibbs, G. Collins, B. Van calster, Gardash Bakhishli, G. Grammatopoulos, A. Price, Adrian Taylor, Melissa S. Murphy, B. Kendrick, A. Palmer
Assess the prognostic value of pre‐operative haemoglobin concentration (Hb) for identifying patients who develop severe post‐operative anaemia or require blood transfusion following primary total hip or knee, or unicompartmental knee arthroplasty (THA, TKA, UKA).
{"title":"Utility of pre‐operative haemoglobin concentration to guide peri‐operative blood tests for hip and knee arthroplasty: A decision curve analysis","authors":"P. Dhiman, V. Gibbs, G. Collins, B. Van calster, Gardash Bakhishli, G. Grammatopoulos, A. Price, Adrian Taylor, Melissa S. Murphy, B. Kendrick, A. Palmer","doi":"10.1111/tme.12873","DOIUrl":"https://doi.org/10.1111/tme.12873","url":null,"abstract":"Assess the prognostic value of pre‐operative haemoglobin concentration (Hb) for identifying patients who develop severe post‐operative anaemia or require blood transfusion following primary total hip or knee, or unicompartmental knee arthroplasty (THA, TKA, UKA).","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121687259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Ferguson, E. Dawe-Lane, Zaynah Khan, C. Reynolds, K. Davison, D. Edge, S. Brailsford
We explore the role of trust, distrust, and the prevailing socio‐political context to better understand why people from ethnic minority communities are less likely to be blood donors compared to people from White communities. Recruiting more ethnic minority donors will enhance representativeness, reduce inequality, and help meet the clinical need to increase the proportion of blood with Ro Kell antigen to treat Sickle Cell Disease (SCD).
{"title":"Trust and distrust: Identifying recruitment targets for ethnic minority blood donors","authors":"E. Ferguson, E. Dawe-Lane, Zaynah Khan, C. Reynolds, K. Davison, D. Edge, S. Brailsford","doi":"10.1111/tme.12867","DOIUrl":"https://doi.org/10.1111/tme.12867","url":null,"abstract":"We explore the role of trust, distrust, and the prevailing socio‐political context to better understand why people from ethnic minority communities are less likely to be blood donors compared to people from White communities. Recruiting more ethnic minority donors will enhance representativeness, reduce inequality, and help meet the clinical need to increase the proportion of blood with Ro Kell antigen to treat Sickle Cell Disease (SCD).","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"183 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127033314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Lee, Jamie Murphy, Rasheed Al-Khudairi, A. Sturdy, T. Mahungu, T. Haque, P. Griffiths, J. Tosswill, D. Irish
In the United Kingdom, organ donors/recipients are screened for evidence of human T‐cell leukaemia virus type‐1 and type‐2 (HTLV‐1/2) infections. Since the United Kingdom is a low prevalence country for HTLV infections, a screening assay with high sensitivity and specificity is required. Samples with repeat reactivity on antibody testing are sent to a reference lab for confirmatory serological and molecular testing. In the case of donor screen, this leads to delays in the release of organs and can result in wastage. We aim to assess whether a signal/cut‐off (S/CO) ratio higher than the manufacturer's recommendation of 1.0 in the Abbott Architect antibody assay is a reliable measure of HTLV‐1/2 infection.
{"title":"Diagnostic accuracy of Abbott Architect Assay as a screening tool for human T‐cell leukaemia virus type‐1 and type‐2 infection in a London teaching hospital with a large solid organ transplant centre","authors":"N. Lee, Jamie Murphy, Rasheed Al-Khudairi, A. Sturdy, T. Mahungu, T. Haque, P. Griffiths, J. Tosswill, D. Irish","doi":"10.1111/tme.12866","DOIUrl":"https://doi.org/10.1111/tme.12866","url":null,"abstract":"In the United Kingdom, organ donors/recipients are screened for evidence of human T‐cell leukaemia virus type‐1 and type‐2 (HTLV‐1/2) infections. Since the United Kingdom is a low prevalence country for HTLV infections, a screening assay with high sensitivity and specificity is required. Samples with repeat reactivity on antibody testing are sent to a reference lab for confirmatory serological and molecular testing. In the case of donor screen, this leads to delays in the release of organs and can result in wastage. We aim to assess whether a signal/cut‐off (S/CO) ratio higher than the manufacturer's recommendation of 1.0 in the Abbott Architect antibody assay is a reliable measure of HTLV‐1/2 infection.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123137633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Gahan, Carley N. Gemelli, Sarah P Kruse, Tanya E. Davison
We aimed to evaluate the acceptability, feasibility, and understanding of a donor ethnic‐ancestry question with Australian blood donors.
我们的目的是评估澳大利亚献血者对献血者种族血统问题的可接受性、可行性和理解。
{"title":"Designing and testing an ethnic‐ancestry question for Australian blood donors: Acceptability, feasibility, and understanding","authors":"L. Gahan, Carley N. Gemelli, Sarah P Kruse, Tanya E. Davison","doi":"10.1111/tme.12865","DOIUrl":"https://doi.org/10.1111/tme.12865","url":null,"abstract":"We aimed to evaluate the acceptability, feasibility, and understanding of a donor ethnic‐ancestry question with Australian blood donors.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126246243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Mehew, Rachel J. Johnson, David J Roberts, A. Griffiths, H. Harvala
Convalescent plasma containing high levels of SARS‐CoV‐2 antibodies has been studied as a possible treatment for COVID‐19. Better understanding of predictors of high antibody levels is needed for improving supply of high‐quality therapeutic plasma.
{"title":"Convalescent plasma for COVID‐19: Donor demographic factors associated high neutralising antibody titres","authors":"J. Mehew, Rachel J. Johnson, David J Roberts, A. Griffiths, H. Harvala","doi":"10.1111/tme.12868","DOIUrl":"https://doi.org/10.1111/tme.12868","url":null,"abstract":"Convalescent plasma containing high levels of SARS‐CoV‐2 antibodies has been studied as a possible treatment for COVID‐19. Better understanding of predictors of high antibody levels is needed for improving supply of high‐quality therapeutic plasma.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121514604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dear Sir, The National Institute for Biological Standards and Control (NIBSC) has been issuing the British Standard for Anti-D, used to calibrate the AutoAnalyser for quantitation of anti-D in patient plasma, for some 40 years. Recently, whilst establishing the current 3rd British Standard (CE Marked) for anti-D in plasma, we realised that, although there are passing references in the literature, the origins and establishment of this standard have never been published. First, we would like to provide a historical overview of how the first working standard was originally established and, second, how it has evolved, by reporting on the collaborative study to establish the current 3rd British Standard (CE Marked) for anti-D in plasma. In October 1971, the Directors of the UK National Transfusion Centres decided that a national working standard for anti-D, for use in automated assay techniques, was required for routine use in hospitals. The candidate standard was prepared from 23 L of pooled citrated plasma containing incomplete (IgG) anti-D from donors in early, mid and late stages of immunisation. Plasma was recalcified, the clot removed and excess calcium absorbed on an ion-exchange resin, followed by 0.45 μm filtration into three separate containers for sterile storage. Subsequently, the material from each of the three containers was distributed (0.5 mL) into glass ampoules and lyophilised to generate three batches (NIBSC filling codes: 72/229; 73/515; and 73/517) and stored at −20 C. Analyses showed that each ampoule contained 0.58% residual moisture and 0.14% oxygen. The three batches of lyophilised material, described above, were distributed in a collaborative study with the aim to establish a British Working Standard. These candidates were assayed against the International Standard (IS; 64/19) for Anti-D Incomplete Blood Typing Serum using groups O, R1R1 and R2r cells on the AutoAnalyser by five UK clinical laboratories. The results showed that there was no difference between the dose-response curves of the three candidate batches of lyophilised material. Consequently, data for all three batches were pooled for each laboratory, and anti-D potencies, relative to the IS, were determined by parallel-line analysis. There were signs of differences with the slope of pooled candidate data, which tended to be steeper than that of the IS, although non-parallelism (P <0 .01) was only found in 2 of 80 assays, no more than would be expected by chance. Deviations from linearity were observed in 8 of 80 assays with a very small error, which was overcome by reducing the weights of these assays in the potency calculations. The potency estimates varied between laboratories. Two laboratories obtained potencies of 14 IU/ampoule, and the other three laboratories estimated around 10 IU/ampoule. The overall mean potency from all laboratories was 11.54 IU/ampoule (95% confidence interval [CI]: 11.00-12.11). The discrepancy between laboratories was presumed to be a
{"title":"The British Standard for (European Conformity[CE] Marked) Anti‐D: Its rarely discussed but important role in quantitating anti‐D in patient plasma","authors":"B. Fox, J. Hockley, L. Studholme","doi":"10.1111/tme.12649","DOIUrl":"https://doi.org/10.1111/tme.12649","url":null,"abstract":"Dear Sir, The National Institute for Biological Standards and Control (NIBSC) has been issuing the British Standard for Anti-D, used to calibrate the AutoAnalyser for quantitation of anti-D in patient plasma, for some 40 years. Recently, whilst establishing the current 3rd British Standard (CE Marked) for anti-D in plasma, we realised that, although there are passing references in the literature, the origins and establishment of this standard have never been published. First, we would like to provide a historical overview of how the first working standard was originally established and, second, how it has evolved, by reporting on the collaborative study to establish the current 3rd British Standard (CE Marked) for anti-D in plasma. In October 1971, the Directors of the UK National Transfusion Centres decided that a national working standard for anti-D, for use in automated assay techniques, was required for routine use in hospitals. The candidate standard was prepared from 23 L of pooled citrated plasma containing incomplete (IgG) anti-D from donors in early, mid and late stages of immunisation. Plasma was recalcified, the clot removed and excess calcium absorbed on an ion-exchange resin, followed by 0.45 μm filtration into three separate containers for sterile storage. Subsequently, the material from each of the three containers was distributed (0.5 mL) into glass ampoules and lyophilised to generate three batches (NIBSC filling codes: 72/229; 73/515; and 73/517) and stored at −20 C. Analyses showed that each ampoule contained 0.58% residual moisture and 0.14% oxygen. The three batches of lyophilised material, described above, were distributed in a collaborative study with the aim to establish a British Working Standard. These candidates were assayed against the International Standard (IS; 64/19) for Anti-D Incomplete Blood Typing Serum using groups O, R1R1 and R2r cells on the AutoAnalyser by five UK clinical laboratories. The results showed that there was no difference between the dose-response curves of the three candidate batches of lyophilised material. Consequently, data for all three batches were pooled for each laboratory, and anti-D potencies, relative to the IS, were determined by parallel-line analysis. There were signs of differences with the slope of pooled candidate data, which tended to be steeper than that of the IS, although non-parallelism (P <0 .01) was only found in 2 of 80 assays, no more than would be expected by chance. Deviations from linearity were observed in 8 of 80 assays with a very small error, which was overcome by reducing the weights of these assays in the potency calculations. The potency estimates varied between laboratories. Two laboratories obtained potencies of 14 IU/ampoule, and the other three laboratories estimated around 10 IU/ampoule. The overall mean potency from all laboratories was 11.54 IU/ampoule (95% confidence interval [CI]: 11.00-12.11). The discrepancy between laboratories was presumed to be a ","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" 500","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"113946739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Hashem, Ahmed M. Hassan, A. Tolah, M. Alsaadi, Q. Abunada, G. Damanhouri, S. El-Kafrawy, M. Picard-Maureau, E. Azhar, S. Hindawi
This study aimed to assess the efficacy of the INTERCEPT™ Blood System [amotosalen/ultraviolet A (UVA) light] to reduce the risk of Middle East respiratory syndrome‐Coronavirus (MERS‐CoV) transmission by human platelet concentrates.
{"title":"Amotosalen and ultraviolet A light efficiently inactivate MERS‐coronavirus in human platelet concentrates","authors":"A. Hashem, Ahmed M. Hassan, A. Tolah, M. Alsaadi, Q. Abunada, G. Damanhouri, S. El-Kafrawy, M. Picard-Maureau, E. Azhar, S. Hindawi","doi":"10.1111/tme.12638","DOIUrl":"https://doi.org/10.1111/tme.12638","url":null,"abstract":"This study aimed to assess the efficacy of the INTERCEPT™ Blood System [amotosalen/ultraviolet A (UVA) light] to reduce the risk of Middle East respiratory syndrome‐Coronavirus (MERS‐CoV) transmission by human platelet concentrates.","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126553146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2006-06-01DOI: 10.1111/j.1365-3148.2006.00660.x
s of selected papers presented at the 39 Annual Scientific Meeting of the Australian and New Zealand Society of Blood Transfusion, Sydney Convention and Exhibition Centre, Darling Harbour, Sydney, Australia,
{"title":"Abstracts of selected papers presented at the 39th Annual Scientific Meeting of the Australian and New Zealand Society of Blood Transfusion, Sydney Convention and Exhibition Centre, Darling Harbour, Sydney, Australia, 16–19 October 2005","authors":"","doi":"10.1111/j.1365-3148.2006.00660.x","DOIUrl":"https://doi.org/10.1111/j.1365-3148.2006.00660.x","url":null,"abstract":"s of selected papers presented at the 39 Annual Scientific Meeting of the Australian and New Zealand Society of Blood Transfusion, Sydney Convention and Exhibition Centre, Darling Harbour, Sydney, Australia,","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"194 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122387865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：